天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片

PAD2 Monoclonal Antibody (Clone 9F7)

PAD2 Monoclonal Antibody (Clone 9F7) Struktur
CAS-Nr.
Englisch Name:
PAD2 Monoclonal Antibody (Clone 9F7)
Synonyma:
PAD2 Monoclonal Antibody (Clone 9F7)
CBNumber:
CB64814999
Summenformel:
Molgewicht:
0
MOL-Datei:
Mol file

PAD2 Monoclonal Antibody (Clone 9F7) Eigenschaften

Sicherheit

PAD2 Monoclonal Antibody (Clone 9F7) Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung

Protein Arginine Deiminases (PADs) are guanidino-modifying enzymes belonging to the amidinotransferase superfamily and are designated PAD1-4 and PAD6. PAD enzymes catalyze the conversion of specific arginine residues to citrulline in a calcium-dependent manner. All enzymes are cytosolic except for PAD4 which is localized in the nucleus. PAD2 is the most widely expressed member and also the most conserved across mammalian species, implying it is the ancestral homologue of the PADs. Overexpression of PAD2 results in myelin loss in a transgenic model, potentially linking PAD2 activity to multiple sclerosis. It has also been shown to modify vimentin and β/γ-actin, potentially aggravating the autoantigen response in rheumatoid arthritis. PAD2 may also play a role in transcriptional regulation, as it has been shown capable of citrullinating histones, particularly H3 during mammalian reproductive cycles, when it is transcriptionally activated in the nucleus. The predicted molecular weight of PAD2 is 75.6 kDa and Cayman’s PAD2 Monoclonal Antibody (Clone 9F7) detects a band at 75 kDa by western blot.

PAD2 Monoclonal Antibody (Clone 9F7) Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte


PAD2 Monoclonal Antibody (Clone 9F7) Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.

Global( 6)Lieferanten
Firmenname Telefon E-Mail Land Produktkatalog Edge Rate
Cayman Chemical Company (800)364-9897
Caymanname@qq.com CHINA 21570 58

  • PAD2 Monoclonal Antibody (Clone 9F7)
Copyright 2019 ? ChemicalBook. All rights reserved